Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
303 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07698366 | Breast Ultrasound Screening in Elderly Women: A Multicenter Cluster Randomized Trial | recruiting | N/A | 80,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07831330 | Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 |
| Sep 21, 2026 |
| clinicaltrials |
| NCT07351474 | Remimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy | completed | N/A | 147 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07809698 | CT-AI Breast Cancer Opportunistic Screening Health Examination Study | not yet recruiting | N/A | 30,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07806084 | Correlation Between ANC and Bone Pain in Breast Cancer Patients Receiving Long-Acting G-CSF(Bone Pain) | not yet recruiting | — | 132 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 8, 2026 | clinicaltrials |
| NCT05900882 | SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease | completed | Phase 2 | 29 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06700863 | Screening of Biomarkers and Related Mechanisms for RIX(RIX) | completed | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07799649 | ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR | not yet recruiting | — | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07763938 | CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies | not yet recruiting | Phase 1 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07438106 | A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer | recruiting | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06577194 | Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01) | active not recruiting | Phase 2 | 35 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06375707 | First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer | completed | Phase 2 | 74 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07746245 | The Efficacy of CAPCT in Patients With PTCL | not yet recruiting | Phase 2 | 58 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04098471 | Total Meso-rectal Excision Versus Transanal Local Excision Followed by Radiotherapy for T2N0M0 Distal Rectal Cancer | recruiting | N/A | 168 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07731828 | Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial | recruiting | Phase 2 | 35 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07718490 | Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer | recruiting | Phase 2 | 43 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07719556 | Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) | recruiting | Phase 2 | 39 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06543992 | Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis | recruiting | Phase 2 | 22 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07180303 | Colorectal Cancer Screening in Chinese Rural Communities(SMART-CRC) | completed | N/A | 20,026 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07464756 | SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer | recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07684274 | Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics | not yet recruiting | — | 290 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07685236 | A Biomarker Exploration Study for Predicting Localization of Recurrence and Metastasis in Colorectal Cancer (PROBE Study)(PROBE) | not yet recruiting | — | 586 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07677956 | Safety of Breast-Conserving Surgery for Multifocal or Multicentric Breast Cancer | not yet recruiting | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07671378 | A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients | recruiting | Phase 2 | 24 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07668362 | Prospective Cohort Study of Local Recurrence After Radical Breast Cancer Resection | not yet recruiting | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jun 25, 2026 | clinicaltrials |
| NCT07668453 | An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies | recruiting | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07669740 | A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy | not yet recruiting | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06884670 | Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study | completed | Phase 2 | 130 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07646639 | Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC(PRIDE-02) | recruiting | Phase 2 | 122 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07641114 | Behavior Change Wheel-Based Music Listening for Chemotherapy-Related Cognitive Impairment in Breast Cancer Patients(BCW-MUSIC) | completed | N/A | 90 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07628595 | Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 19 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07628582 | A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies | not yet recruiting | Phase 1 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07622836 | A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer. | recruiting | N/A | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07608978 | Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes(Pola-ZRCHP) | recruiting | Phase 2 | 35 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07394387 | Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. | recruiting | Phase 2 | 58 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07589699 | Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP | not yet recruiting | Phase 4 | 59 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 15, 2026 | clinicaltrials |
| NCT07002112 | The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07587983 | Real-World Treatment of ADC-Resistant HER2-Low Advanced Breast Cancer | completed | — | 220 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07563543 | RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas | not yet recruiting | Early Phase 1 | 10 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 4, 2026 | clinicaltrials |
| NCT06817954 | To Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer (NJMU-Reconstruction Cohort) | recruiting | N/A | 800 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06759636 | A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11(FRIENDS-01) | recruiting | Phase 3 | 88 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07523789 | Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC | not yet recruiting | — | 201 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07277439 | Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma | recruiting | Phase 2 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07396467 | Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis(IPF-LC-IO) | active not recruiting | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07474324 | Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial | recruiting | Phase 2 | 124 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07455019 | A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer | recruiting | Phase 2 | 28 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07448324 | Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07446452 | Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study | recruiting | Phase 2 | 37 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07418190 | Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma | recruiting | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410520 | PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
Data updated 21 hours agoSource updated unknownsource: clinicaltrials